Topoisomerase IIIα controls alternative lengthening of telomeres
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.116066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Prashant Khandagale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20…. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type I, Telomere Homeostasis, Telomere. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Alternative lengthening of telomeres (ALT) is a homologous recombination-dependent telomere elongation mechanism utilized by at least 10%-15% of all cancers. Here, we identify that the DNA topoisomerase, topoisomerase III⍺ (TOP3A), is enriched at the telomeres of ALT cells but not at the telomeres of telomerase (Tel)-positive cancer cells. We demonstrate that TOP3A stabilizes the shelterin complex in ALT cancer cell lines but not in Tel cells and that long non-coding telomeric-repeat containing RNA (TERRA) enrichment at telomeres depends on TOP3A. TOP3A also promotes the generation of single-stranded telomeric C-strand (ssTeloC) DNA, a recently discovered marker for ALT. Additionally, we find that inducing break-associated TOP3A-DNA-protein crosslinks in ALT cells suppresses TERRA enrichment and destabilizes the shelterin complex. Taken together, these observations uncover unexplored functions of TOP3A at ALT telomeres and suggest the potential of developing an ALT-specific cancer therapeutic strategy targeting TOP3A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: khandagalepr@nih.gov.
- Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Department of Pharmacology, Physiology and Drug Development,…
- Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
- Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: pommier@nih.gov.
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- National Institutes of Health
- Center for Cancer Research
- National Cancer Institute
Zitieren
APA
Khandagale, P., Sun, Y., Taniyama, D., Saha, S., Saha, L. K., & Pommier, Y. (2025). Topoisomerase IIIα controls alternative lengthening of telomeres. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116066
Vancouver
Khandagale P, Sun Y, Taniyama D, Saha S, Saha LK, Pommier Y. Topoisomerase IIIα controls alternative lengthening of telomeres. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116066
BibTeX
@article{Khandagale2025,
author = {Khandagale, Prashant and Sun, Yilun and Taniyama, Daiki and Saha, Sourav and Saha, Liton Kumar and Pommier, Yves},
title = {Topoisomerase IIIα controls alternative lengthening of telomeres},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.116066}
}
EUVIMED